Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hepatitis C – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Browse the full report @ http://www.orbisresearch.com/reports/index/hepatitis-c-pipeline-review-h2-2016 .
The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C.
Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/146102 .
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Request a sample Hepatitis C-Pipeline Review, H2 2016 Report
Companies Mentioned in this report are :
3-V Biosciences, Inc.
AIMM Therapeutics B.V.
Akshaya Bio Inc.
Amarillo Biosciences, Inc.
Amarna Therapeutics B.V.
ARA Healthcare Pvt. Ltd.
Aviragen Therapeutics, Inc.
Beijing Kawin Technology Share-Holding Co., Ltd.
Benitec Biopharma Limited
Beta Pharma, Inc.
Bionor Pharma ASA
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Chugai Pharmaceutical Co., Ltd.
Cocrystal Pharma, Inc.
Conatus Pharmaceuticals Inc.
ContraVir Pharmaceuticals, Inc.
Digna Biotech, S.L.
Enanta Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GinkgoPharma Co. Ltd.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Inovio Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
JN-International Medical Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Merck & Co., Inc.
Microbio Co., Ltd.
MultiCell Technologies, Inc.
NeuroVive Pharmaceutical AB
NovaTarg Therapeutics, Inc
Ono Pharmaceutical Co., Ltd.
Polaris Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Regulus Therapeutics Inc.
Rodos BioTarget GmbH
Savoy Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd.
Therapix Biosciences Ltd.
Therapure Biopharma Inc.
Vakzine Projekt Management GmbH
Vertex Pharmaceuticals Incorporated
WhanIn Pharmaceutical Co., Ltd.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com